Teriparatide: Treatment of osteoporosis, parathyroid hormone analog

Drugs of the Future

Volumn 25, Issue 8, 2000, Pages 803-808

  Revel, L ^a   Sorbera, L A ^a   Martin, L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; PARATHYROID HORMONE[1-34];

ARTICLE; BONE DENSITY; BONE MASS; BONE STRENGTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

EID: 0033775918     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.08.589014     Document Type: Article

References (29)

1. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone
2. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovarectomized rats
3. Comparison of the anabolic effects of the synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats
4. Parathyroid hormone-related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor
5. Nuclear localization of the type 1 PTH/PTHrP receptor in rat tissues
6. Comparison of recombinant human PTH(1-34) (LY-333334) with a C-terminally substituted analog of human PTH-related protein (1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats
7. Anabolic actions of parathyroid hormone on bone
8. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats
9. Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1-34
10. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment
11. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats
12. Low dose effects of PTH on tissue composition in prevention and intervention in rat models
13. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34)
14. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
15. Bone changes with long-term administration of low dose 1-34 human PTH on adult beagles
16. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)2D3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone
17. Animal models of cortical porosity
18. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34)
19. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits
20. In primates, treatment with PTH (1-34), LY333334, increases bone strength at trabecular bone sites without compromising the strength of cortical bone
21. Daily treatment with human recombinant parathyroid hormone (1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys
22. Effects of continuation or withdrawal of PTH[1-34] treatment on spine and proximal tibia BMD in ovariectomized monkeys
23. Pharmacokinetic profile of LY333334, biosynthetic human parathyroid hormone (hPTH) (1-34), and serum biochemistry after anabolic or catabolic injection protocol
24. Parathyroid hormone (hPTH 1-34) and estrogen dramatically increases bone density in postmenopausal osteoporosis: A placebo-controlled randomized trial
25. Parathyroid hormone in combination with estrogen dramatically reduces vertebral fracture risk
26. Does treatment with parathyroid hormone increase vertebral size?
27. Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis